Enlivex

Could humans live to 150 years? Longevity science has moved that question from theoretical to genuinely worth asking. But the more pressing question may be a different one: do we have the tools to make those extra decades worth living? Living longer only matters if the body can keep up. Mobility, independence, the ability to move through daily life without pain; these are key considerations when we talk about extending lifespan. Osteoarthritis already affects more than 300 million people worldwide. It is one of the most common reasons people lose function as they age, and one of the clearest examples of why extending lifespan without addressing physical decline is an incomplete picture. At Enlivex, this is the problem we are working to solve. Allocetra™ is a cell therapy in clinical development designed to reprogram dysfunctional macrophages and address the chronic inflammation that progressively limits joint mobility. Quality longevity is not about adding years. It is about preserving the capacity to use them.

Prediction markets are generating over $3 billion in annualized revenue today. According to a February 2026 report by U.S. bank, Citizens, that figure is on track to reach $10 billion by 2030. Citizens attributes the trajectory to rising trading volumes, improving market infrastructure, and the early stages of institutional capital entry. Their analysts compare the current growth curve to the early evolution of listed derivatives and digital assets. That institutional recognition matters. It signals that prediction markets are no longer a speculative footnote in global finance. They are becoming a structural layer of it. Our RAIN token treasury position was designed to sit inside that structural shift. As prediction markets scale, a programmatic 2.5% buyback-and-burn mechanism contracts RAIN token supply automatically. Enlivex holds an exclusive fixed-price option on up to $918 million of RAIN, accessible through a regulated Nasdaq ticker. The growth thesis is no longer speculative. It is being priced by Wall Street.

Enlivex is now part of the $1 billion tokenized stock market. Ondo Finance has launched ENLVon on its Global Markets platform, a tokenized representation of ENLV ordinary shares that extends the investment reach of our dual-strategy model from traditional capital markets into blockchain infrastructure. This development matters for two reasons. First, it opens a direct gateway for non-U.S. retail and institutional investors to access the ENLV economic structure without requiring traditional brokerage accounts, meaningfully lowering the barrier to entry for a global investor base. Second, tokenized shares introduce a new layer of structural utility, enabling ENLV to function as collateral within lending and yield-generating frameworks. The tokenized equity market is growing. By positioning ENLV within that infrastructure, we are ensuring that access to our dual-strategy model scales alongside it.

Enlivex 2025 Year-End Earnings. In 2025, we became the first public company to anchor our corporate treasury in the prediction markets economy. We built a programmatic treasury around the Rain protocol, whose economics are tied directly to the growth of global forecasting markets, securing the capital foundation of our quality longevity mission without issuing a single new share. At the same time, our quality longevity therapy continued to advance through the clinic. This week, the FDA cleared our Phase 2b trial in patients with age-related primary knee osteoarthritis, a condition affecting more than 300 million people globally. These numbers are the result of that architecture working as intended. One ticker. Two Strategies. $ENLV

Enlivex 2025 Total Net Profit: $1.23 Billion with $25.48 Earnings Per Share. Twelve months ago, Enlivex posted a net loss of $15 million. That is what a clinical-stage company looks like before its capital structure is working. When we architected the Enlivex treasury strategy, the logic was deliberate. A quality longevity therapy funded by a treasury tied to the economics of the global prediction markets industry. Two engines generating value independently, without issuing a single new share to get there. We view the RAIN treasury as a capital engine that compounds as forecasting volumes scale. Alongside it, Allocetra continues to advance, with FDA clearance for our Phase 2b trial confirmed earlier this week. From -$15M to $1.23B in twelve months. Two engines. One ticker. $ENLV

Prediction markets are no longer a niche experiment. They are becoming the new infrastructure for global information, growing faster than almost any other asset class. The scale of this shift is undeniable. According to a recent report by FalconX annual volumes in the forecasting sector are projected to grow from $64B in 2025 to over $325B in 2026. At Enlivex, we’ve engineered a corporate treasury designed for this new reality. Through a strategic partnership with the Rain Protocol, we’ve secured a capital layer that includes programmatic yield and aggressive anti-dilution protections, establishing the first-ever public company treasury built on the prediction market sector. While others are betting on individual event outcomes, we have created an institutional vehicle that captures the growth of the entire forecasting industry. Through a single, regulated Nasdaq ticker, investors can now gain exposure to the economic momentum of a $325B sector. By anchoring our financial strategy in decentralized infrastructure, we are ensuring that our clinical mission to treat osteoarthritis remains backed by a resilient and sovereign financial engine.